US 2019/0167690 A1 · Immuno-Gene Combination Therapy

Abstract

“In situ vaccination” using immuno-gene therapy has the ability to induce polyclonal anti-tumor responses directed by the patient's immune system. Patients with unresectable MPM received two intrapleural doses of a replication-defective adenoviral vector containing the human interferon-alpha (hIFN-α2b) gene (Ad.IFN) concomitant with a 14-day course of a cyclooxygenase-2 inhibitor (celecoxib), followed by standard first- or second-line cytotoxic chemotherapy. Forty subjects, ECOG PS 0 or 1, were treated: 18 received first-line pemetrexed-based chemotherapy with platinum, 22 received second-line chemotherapy with pemetrexed (n=7) or a gemcitabine-based regimen (n=15). Overall survival rate was significantly higher than historical controls in the second-line group.

Claims13

Dependent claims

A method of treating a human patient comprising:

a. diagnosing in said patient cancer;
and then
b. treating said patient with a first-line treatment regimen;
and then
c. diagnosing in said patient cancer resistant to or recurrent after said first-line treatment regimen;
and then
d. treating said patient with an agent which induces the expression of interferon, in an amount effective to induce interferon expression in a human;
and
e. treating said patient with a second-line treatment regimen comprising treatment selected from the group consisting of:
pemetrexed, gemcitabine, cisplatin and carboplatin.

7 more elements

Dependencies are inferred from the claim text.

Facts

Application

16/268,548Filed 6 Feb 2019

Priority

6 Mar 2016

Published

6 Jun 2019

Term ends

Not estimatedThe source records don’t support an estimate.

Classification21 codes

A61K 31/519
Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim: ortho- or peri-condensed with heterocyclic rings
A61K 9/0019
Galenical forms characterised by the site of application: injectable compositions; Intramuscular, intravenous, arterial, subcutaneous…
A61K 31/415
Having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole: 1,2-Diazoles
A61K 31/555
Heterocyclic compounds: containing heavy metals, e.g. hemin, hematin, melarsoprol

Immuno-Gene Combination Therapy

Life of this patent

Immuno-Gene Combination Therapy

Life of this patent

Abstract

Claims13